Keyphrases
Hereditary Angioedema
100%
C1 Inhibitor
31%
Angioedema Attack
30%
Asthma
29%
Placebo
16%
Allergic Rhinitis
16%
Angioedema
15%
C1 Esterase Inhibitor
14%
Inhaled Corticosteroids
12%
Quality of Life
11%
Nasal Congestion
9%
United States
9%
Rhinitis
9%
Daytime Somnolence
8%
Allergy
8%
Asthma Control
8%
Alpha-1 Antitrypsin Deficiency
7%
Allergist
7%
Congestion
7%
Open-label Extension
7%
Sleep Disturbance
6%
Salmeterol
6%
Icatibant
6%
Daytime Fatigue
5%
Perennial Allergic Rhinitis
5%
Ecallantide
5%
COVID-19
5%
Long-term Prophylaxis
5%
Prophylactic Treatment
5%
Clinical Trials
5%
Asthma Treatment
5%
Treatment Options
5%
Confidence Interval
5%
Adverse Events
5%
Pharmacology, Toxicology and Pharmaceutical Science
Angioneurotic Edema
85%
Complement Component C1s Inhibitor
40%
Asthma
26%
Placebo
18%
Allergic Rhinitis
14%
Diseases
13%
Isoniazid
13%
Adverse Event
13%
Daytime Somnolence
9%
Symptom
9%
Nose Obstruction
8%
Rhinitis
6%
Vasomotor Rhinitis
5%
Sleep Disorder
5%
Coronavirinae
5%
Perennial Rhinitis
5%
Medicine and Dentistry
Hereditary Angioedema
69%
Complement Component C1s Inhibitor
27%
Asthma
18%
Quality of Life
14%
Isoniazid
11%
Angioedema
10%
Placebo
9%
Allergic Rhinitis
8%
Diseases
8%
COVID-19
8%
Rhinitis
6%
Symptom
6%
Alpha 1-Antitrypsin Deficiency
6%
Adverse Event
5%
